The United Kingdom and the United States have finalized a significant bilateral deal that will maintain no levies on British drug products being sold in the American market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has committed to increase expenditure on pharmaceuticals through the public health system. This pledge secures that import taxes on these key exports will be held at zero for a duration of the next three years.
This deal follows recent threats to dramatically increase duties on patented drug products, with figures floated as high as one hundred percent.
"This arrangement with the United Kingdom bolsters the worldwide climate for cutting-edge drugs and introduces much-needed equity to American-British drug exports," a release noted.
Trade Significance
Medicines are one of the the United Kingdom's largest exports to the United States, which is by far the largest destination for large British pharmaceutical firms.
Trade data reveal that in the one-year period to the end of September, the UK sold drugs totaling billions to the US. This figure made up nearly one-fifth of all goods exports in that timeframe.
"This deal safeguards work, boosts funding and paves the way for the UK to establish itself as a worldwide center for medical research," the Business and Trade Secretary remarked.
Detailed British Pledges
The pact entails several key changes from the UK:
- Price Threshold Increase: The UK will increase the affordability limit at which it considers new medicines to be unaffordable by 25%.
- Boosted Medicine Funding: There is a target to double total public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Payback Limit: The percentage manufacturers must refund to the NHS to control costs will be restricted at fifteen percent. Previously, refunds were more than twenty percent.
Recent Tensions
The deal comes amid a ongoing tension between the drug companies and the UK government over medicine costs and NHS adoption.
The disagreement were exacerbated by claims that US patients were charged several times more for the same drugs than patients in the other developed nations.
In recent months, several large manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar expansions have been pledged toward projects in the United States.
One official publicly accepted that the NHS had to increase expenditure on drugs, noting that its expenditure on drugs had declined as a proportion of its overall budget over the last ten years.
